TY - JOUR
T1 - A genome-wide association analysis identifies PDE1A|DNAJC10 locus on chromosome 2 associated with idiopathic pulmonary arterial hypertension in a Japanese population
AU - Kimura, Mai
AU - Tamura, Yuichi
AU - Guignabert, Christophe
AU - Takei, Makoto
AU - Kosaki, Kenjiro
AU - Tanabe, Nobuhiro
AU - Tatsumi, Koichiro
AU - Saji, Tsutomu
AU - Satoh, Toru
AU - Kataoka, Masaharu
AU - Kamitsuji, Shigeo
AU - Kamatani, Naoyuki
AU - Thuillet, Raphaël
AU - Tu, Ly
AU - Humbert, Marc
AU - Fukuda, Keiichi
AU - Sano, Motoaki
N1 - Publisher Copyright:
© Kimura et al.
PY - 2017
Y1 - 2017
N2 - Pulmonary arterial hypertension (PAH) is a lethal disease that often affects the young. Although Bone Morphogenetic Protein Receptor Type 2 gene (BMPR2) mutations are related with idiopathic and heritable PAH, the low penetrance and variable expressivity in PAH suggest the existence of other genetic and/or environmental factors. In this study, we aimed to identify novel genetic factors associated with PAH, irrespective of BMPR2 mutation. We performed genome-wide association study (GWAS) in a Japanese population comprising 44 individuals with idiopathic and heritable PAH, and 2,993 controls. Seven loci identified in the genome-wide study were submitted to the validation study, and a novel susceptibility locus, PDE1A|DNAJC10, was identified that maps to 2q32.1 (rs71427857, P = 7.9 × 10-9, odds ratio in the validation study = 5.18; 95% CI 1.86 - 14.42). We also found the augmentation of PDE1A protein in distal remodeled pulmonary artery walls in idiopathic PAH patients. Given that phosphodiesterase 5 inhibitors are effective for the treatment of idiopathic and heritable PAH, our findings suggest that PDE1A could be a novel therapeutic target of PAH.
AB - Pulmonary arterial hypertension (PAH) is a lethal disease that often affects the young. Although Bone Morphogenetic Protein Receptor Type 2 gene (BMPR2) mutations are related with idiopathic and heritable PAH, the low penetrance and variable expressivity in PAH suggest the existence of other genetic and/or environmental factors. In this study, we aimed to identify novel genetic factors associated with PAH, irrespective of BMPR2 mutation. We performed genome-wide association study (GWAS) in a Japanese population comprising 44 individuals with idiopathic and heritable PAH, and 2,993 controls. Seven loci identified in the genome-wide study were submitted to the validation study, and a novel susceptibility locus, PDE1A|DNAJC10, was identified that maps to 2q32.1 (rs71427857, P = 7.9 × 10-9, odds ratio in the validation study = 5.18; 95% CI 1.86 - 14.42). We also found the augmentation of PDE1A protein in distal remodeled pulmonary artery walls in idiopathic PAH patients. Given that phosphodiesterase 5 inhibitors are effective for the treatment of idiopathic and heritable PAH, our findings suggest that PDE1A could be a novel therapeutic target of PAH.
KW - Genome-wide association study
KW - Novel therapeutic target
KW - Pulmonary arterial hypertension
UR - http://www.scopus.com/inward/record.url?scp=85030084250&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030084250&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.20459
DO - 10.18632/oncotarget.20459
M3 - Article
C2 - 29088834
AN - SCOPUS:85030084250
SN - 1949-2553
VL - 8
SP - 74917
EP - 74926
JO - Oncotarget
JF - Oncotarget
IS - 43
ER -